|VEGF Trap Eye|
The patent is not invalid on any ground alleged. The patent is infringed by VEGF Trap Eye.
Use of a hVEGF antagonist in the preparation of a medicament for the treatment of a non-neoplastic disease or disorder characterised by undesirable excessive neovascularisation, wherein the hVEGF antagonist is:(a) an anti-VEGF antibody or antibody fragment;(b) an anti-VEGF receptor antibody or antibody fragment; or(c) an isolated hVEGF receptor.
I consider that the patent discloses a principle of general application within the meaning of the authorities insofar as it claims anti-VEGF antagonism as a treatment for all non-neoplastic diseases.